See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
Merck & Co., Inc. (MRK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Merck & Co., Inc. (MRK) - free report >>
Image: Bigstock
Incyte Reports Epacadostat Combination Study Initiation
Incyte Corporation (INCY - Free Report) announced that the first patient has been treated in a phase III study (ECHO-301) evaluating epacadostat in combination with Merck & Co. Inc.’s (MRK - Free Report) Keytruda for the first-line treatment of patients with advanced or metastatic melanoma. We expect investors to react positively to the news.
The randomized, double-blind, placebo-controlled study will enroll 600 patients. While the two primary endpoints of the study are progression-free survival and overall survival, key secondary endpoints include objective response rate, safety and tolerability. Incyte anticipates initial data from the ECHO-301 study in 2018.
According to information provided by the company, in the U.S., melanoma accounts for approximately 5% of all new cases of cancer each year. In the EU, there are about 41,000 new cases of melanoma each year, resulting in approximately 11,000 deaths annually.
We note that the ECHO-301 study is sponsored by both Incyte and Merck. Incyte is also collaborating with Merck to evaluate epacadostat in combination with Keytruda in a phase II study (ECHO-202) across multiple tumor types.
Additionally, epacadostat is being evaluated in several phase I and phase II studies in combination with PD-1 and PD-L1 inhibitors across a variety of other cancer histologies.
Incyte is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>